{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T17:22:55Z","timestamp":1649092975408},"reference-count":0,"publisher":"Akademiai Kiado Zrt.","issue":"46","content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2020,11,15]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic> Az inadekv\u00e1t, ar\u00e1nytalan sinuscsom\u00f3-tachycardia a\n                    sz\u00edv nomotop ingerk\u00e9pz\u00e9si zavar\u00e1val j\u00e1r\u00f3, nem ritka klinikai szindr\u00f3ma. A\n                    sz\u00edvritmuszavar-entit\u00e1st a nem paroxysmalis, magas nyugalmi sinusfrekvencia, a\n                    fizikai\/pszich\u00e9s stresszre adott ar\u00e1nytalan sinustachycardia, valamint f\u0151k\u00e9nt\n                    palpit\u00e1ci\u00f3s panaszok jellemzik. <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic> Az ar\u00e1nytalan\n                    sinuscsom\u00f3-tachycardi\u00e1s betegeink gy\u00f3gyszeres kezel\u00e9s\u00e9vel szerzett\n                    tapasztalataink ismertet\u00e9se. <jats:italic>M\u00f3dszerek:<\/jats:italic> 2008 \u00e9s 2018 k\u00f6z\u00f6tt 104\n                    beteget (92 n\u0151, 12 f\u00e9rfi; \u00e1tlag\u00e9letkor 31 \u00b1 10 \u00e9v) kezelt\u00fcnk ezzel a\n                    sz\u00edvritmuszavarral. A betegek kivizsg\u00e1l\u00e1suk ut\u00e1n 12 elvezet\u00e9ses EKG-, terhel\u00e9ses\n                    EKG-, valamint 24 \u00f3r\u00e1s Holter-monitoros EKG-megfigyel\u00e9seken vettek r\u00e9szt a\n                    gy\u00f3gyszeres kezel\u00e9s el\u0151tt \u00e9s ut\u00e1n (bizoprolol: 2 \u00d7 5 mg\/nap; ivabradin: 2 \u00d7 5\n                    mg\/nap). Az \u00e9letmin\u0151s\u00e9g v\u00e1ltoz\u00e1s\u00e1t a European Heart Rhythm Association (EHRA)\n                    t\u00fcneti sk\u00e1l\u00e1ja szerint \u00e1llap\u00edtottuk meg. <jats:italic>Eredm\u00e9nyek:<\/jats:italic> Mindk\u00e9t\n                    gy\u00f3gyszer jelent\u0151sen cs\u00f6kkentette a nyugalmi sinusfrekvenci\u00e1t (kontroll: 102 \u00b1\n                    10\/min; bizoprolol: 78 \u00b1 6\/min; ivabradin: 74 \u00b1 8\/min, mindkett\u0151: p&lt;0,0001).\n                    A gy\u00f3gyszeres kezel\u00e9s n\u00e9lk\u00fcli, 24 \u00f3r\u00e1s Holter-monitoros EKG-felv\u00e9telek sor\u00e1n\n                    m\u00e9rt sz\u00edvfrekvenci\u00e1k (minimum\u2013maximum [\u00e1tlag] sinusfrekvencia\/min) a\n                    kontroll\u00e9rt\u00e9kekr\u0151l (58 \u00b1 8\u2013159 \u00b1 14 [94 \u00b1 6]\/min) mindk\u00e9t gy\u00f3gyszerre egyar\u00e1nt\n                    szignifik\u00e1nsan cs\u00f6kkentek (bizoprolol: 53 \u00b1 7\u2013132 \u00b1 13 [77 \u00b1 9]\/min [mindh\u00e1rom:\n                    p&lt;0,0001]; ivabradin 51 \u00b1 6\u2013134 \u00b1 18 [77 \u00b1 8]\/min [mindh\u00e1rom: p&lt;0,0001]).\n                    A terhel\u00e9ses EKG-vizsg\u00e1latok el\u0151tt (kontroll: 99 \u00b1 13\/min; bizoprolol 81 \u00b1\n                    11\/min [p&lt;0,0001]; ivabradin: 84 \u00b1 10\/min [p&lt;0,0001]) \u00e9s a terhel\u00e9s\n                    cs\u00facspontj\u00e1n m\u00e9rt sinusfrekvenci\u00e1k (kontroll: 164 \u00b1 15\/min; bizoprolol: 140 \u00b1\n                    16\/min [p&lt;0,0001]; ivabradin: 142 \u00b1 14\/min [p&lt;0,0001]) is jelent\u0151sen\n                    m\u00e9rs\u00e9kl\u0151dtek. Az azonos d\u00f3zisban adott k\u00e9t gy\u00f3gyszer sz\u00edvfrekvencia-cs\u00f6kkent\u0151\n                    hat\u00e1sai k\u00f6z\u00f6tt sz\u00e1mottev\u0151 k\u00fcl\u00f6nbs\u00e9get nem tapasztaltunk. Az \u00e9letmin\u0151s\u00e9get\n                    t\u00fckr\u00f6z\u0151 EHRA t\u00fcneti sk\u00e1l\u00e1n (kontroll: 2,3 \u00b1 0,7) mind a bizoprolol (1,4 \u00b1 1,4;\n                    p&lt;0,0001), mind az ivabradin (1,1 \u00b1 0,2; p&lt;0,0001) egyform\u00e1n cs\u00f6kkentette\n                    a betegek t\u00fcneteit, panaszait. Sz\u00e1mottev\u0151 cardiovascularis mell\u00e9khat\u00e1s egyik\n                    betegcsoportban sem jelentkezett. <jats:italic>K\u00f6vetkeztet\u00e9sek:<\/jats:italic> Vizsg\u00e1lati\n                    eredm\u00e9nyeink alapj\u00e1n meg\u00e1llap\u00edthat\u00f3, hogy az ar\u00e1nytalan sinuscsom\u00f3-tachycardi\u00e1s\n                    betegek gy\u00f3gyszeres kezel\u00e9s\u00e9re: (1) a kardiospecifikus adrenerg b\u00e9ta-blokkol\u00f3\n                    bizoprolol \u00e9s az If-csatorna-g\u00e1tl\u00f3 ivabradin egyar\u00e1nt hat\u00e9konynak \u00e9s\n                    biztons\u00e1gosnak bizonyult; (2) az azonos adagban adott k\u00e9t gy\u00f3gyszer hat\u00e9konys\u00e1ga\n                    k\u00f6z\u00f6tt sz\u00e1mottev\u0151 k\u00fcl\u00f6nbs\u00e9g nem volt; (3) a gy\u00f3gyszeres kezel\u00e9s nemcsak a\n                    sinusfrekvenci\u00e1t cs\u00f6kkentette, hanem a betegek panaszait, t\u00fcneteit is\n                    m\u00e9rs\u00e9kelte. Orv Hetil. 2020; 161(46): 1953\u20131958.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold>\n                    <jats:italic>Introduction:<\/jats:italic> The inadequate, inappropriate sinus-node\n                    tachycardia is not a rare clinical syndrome, defined as a disturbance of the\n                    nomotopic impulse formation of the heart. This cardiac arrhythmic entity is\n                    characterized by a non-paroxismal, increased sinus rate at rest, and\/or\n                    inadequate response to physical and\/or emotional stress and palpitations.\n                        <jats:italic>Objective:<\/jats:italic> The aim of this study was to describe our\n                    experiences with pharmacological therapy of patients with inappropriate sinus\n                    tachycardia syndrome. <jats:italic>Methods:<\/jats:italic> Between 2008 and 2018, 104\n                    patients (92 women, 12 men, mean age: 31 \u00b1 10 years) were treated with this\n                    cardiac arrhythmia entity. All patients underwent 12-lead ECG, 24-hour\n                    Holter-ECG monitoring and standard bicycle dynamic exercise tests before and\n                    after drug treatment (bisoprolol: 5 mg bid; ivabradine: 5 mg bid). Changes in\n                    the quality of life were estimated by using the European Heart Rhythm\n                    Association (EHRA) score. <jats:italic>Results:<\/jats:italic> Both drugs decreased\n                    significantly the resting heart rate (control: 102 \u00b1 10\/min; bisoprolol 78 \u00b1\n                    6\/min (p&lt;0.0001), ivabradine: 74 \u00b1 8\/min (p&lt;0.0001). The results of the\n                    parameters of the 24-hour Holter ECG recordings (expressed as minimal\u2013maximal\n                    [average] heart rate\/min) with drug therapy showed a significant decrease from\n                    control values in all three parameters: control 58 \u00b1 8\u2013159 \u00b1 14 (94 \u00b1 6)\/min;\n                    bisoprolol 53 \u00b1 7\u2013132 \u00b113 (77 \u00b1 9)\/min (all three: p&lt;0.0001); ivabradine: 51\n                    \u00b1 6\u2013134 \u00b1 18 (77 \u00b1 8)\/min (all three: p&lt;0.0001). The sinus rate reduced\n                    significantly both before the bicycle dynamic exercise tests (control: 99 \u00b1\n                    13\/min; bisoprolol: 81 \u00b1 11\/min [p&lt;0.0001]; ivabradine: 84 \u00b1 10\/min\n                    [p&lt;0.0001]) and at the peaks of the exercise test (control: 164 \u00b1 15\/min;\n                    bisoprolol: 140 \u00b1 16\/min [p&lt;0.0001]; ivabradine 142 \u00b1 14\/min [p&lt;0.0001]).\n                    The heart rate reducing effects of the two drugs did not differ significantly.\n                    The EHRA quality of life score was equally improved by the two drugs (control:\n                    2.3 \u00b1 0.7; bisoprolol: 1.4 \u00b1 1.4 [p&lt;0.0001]; ivabradine: 1.1 \u00b1 0.2\n                    [p&lt;0.0001]). No cardiovascular side effects were observed while taking\n                    bisoprolol or ivabradine. <jats:italic>Conclusions:<\/jats:italic> Based on our clinical\n                    results, it can be pointed out that in the drug therapy of patients with\n                    inappropriate sinus node tachycardia: (1) bisoprolol (5 mg bid) and ivabradine\n                    (5 mg bid) proved to be equally effective and safe; (2) the heart rate reducing\n                    effect of the two drugs \u2013 given in the same dosage \u2013 did not differ\n                    considerably; (3) the pharmacological therapy significantly decreased not only\n                    the sinus frequency, but also reduced the symptoms of the patients. Orv Hetil.\n                    2020; 161(46): 1953\u20131958.<\/jats:p>","DOI":"10.1556\/650.2020.31887","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T05:18:03Z","timestamp":1605676683000},"page":"1953-1958","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":0,"title":["Inadekv\u00e1t, ar\u00e1nytalan sinuscsom\u00f3-tachycardia: egy r\u00e9gi sz\u00edvritmuszavar \u00faj megvil\u00e1g\u00edt\u00e1sban (II.)"],"prefix":"10.1556","volume":"161","author":[{"given":"J\u00f3zsef","family":"Borbola","sequence":"first","affiliation":[{"name":"1 Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly, Elektrofiziol\u00f3giai \u00e9s Pacemaker Ter\u00e1pi\u00e1s Oszt\u00e1ly, Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiol\u00f3giai Int\u00e9zet, Budapest, Haller u. 29., 1096"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csaba","family":"F\u00f6ldesi","sequence":"additional","affiliation":[{"name":"1 Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly, Elektrofiziol\u00f3giai \u00e9s Pacemaker Ter\u00e1pi\u00e1s Oszt\u00e1ly, Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiol\u00f3giai Int\u00e9zet, Budapest, Haller u. 29., 1096"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Kardos","sequence":"additional","affiliation":[{"name":"1 Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly, Elektrofiziol\u00f3giai \u00e9s Pacemaker Ter\u00e1pi\u00e1s Oszt\u00e1ly, Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiol\u00f3giai Int\u00e9zet, Budapest, Haller u. 29., 1096"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Som","sequence":"additional","affiliation":[{"name":"1 Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly, Elektrofiziol\u00f3giai \u00e9s Pacemaker Ter\u00e1pi\u00e1s Oszt\u00e1ly, Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiol\u00f3giai Int\u00e9zet, Budapest, Haller u. 29., 1096"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/161\/46\/article-p1953.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/161\/46\/article-p1953.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T01:13:05Z","timestamp":1633914785000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/161\/46\/article-p1953.xml"}},"subtitle":["Gy\u00f3gyszeres kezel\u00e9ssel szerzett\n                    tapasztalataink"],"short-title":[],"issued":{"date-parts":[[2020,11,15]]},"references-count":0,"journal-issue":{"issue":"46"},"URL":"https:\/\/doi.org\/10.1556\/650.2020.31887","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,15]]}}}